Last reviewed · How we verify
Uteplex (URIDINE TRIPHOSPHATE)
Uteplex (generic name: URIDINE TRIPHOSPHATE) is a uridine triphosphate drug. It is currently in Phase 3 development.
Uteplex works by binding to the P2Y purinoceptor 2, a receptor involved in various cellular processes.
Uteplex, also known as Uridine Triphosphate, is a small molecule drug that targets the P2Y purinoceptor 2. It is classified as a uridine triphosphate and its mechanism of action is not well-documented. There is limited information available on Uteplex, including its commercial status, approved indications, and safety considerations. Further research is needed to fully understand its properties and potential uses. As a result, it is difficult to provide a comprehensive summary of Uteplex at this time.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | URIDINE TRIPHOSPHATE |
|---|---|
| Drug class | uridine triphosphate |
| Target | P2Y purinoceptor 11, P2Y purinoceptor 4, P2Y purinoceptor 6 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Mechanism of action
Imagine your cells have special locks on them, and Uteplex is a key that fits into one of those locks. When it binds, it can trigger a response that helps the cell do its job. This can be important for things like cell growth and communication.
Approved indications
Common side effects
Key clinical trials
- RegoNivo vs Standard of Care Chemotherapy in AGOC (PHASE3)
- CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X) (PHASE2)
- Pharmacological Treatment on the Recovery of Neurosensory Disturbance After Bilateral Sagittal Split Osteotomy (PHASE2,PHASE3)
- Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults (EARLY_PHASE1)
- A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) (PHASE2)
- A Study to Diagnose Lung Cancer by Sputum Cytology (01-312) (PHASE3)
- Study of Uridine Triphosphate (UTP) as an Aerosol Spray for Cystic Fibrosis (NA)
- INS316 Compared With Saline for Sputum Collection in Diagnosing Lung Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Uteplex CI brief — competitive landscape report
- Uteplex updates RSS · CI watch RSS
Frequently asked questions about Uteplex
What is Uteplex?
How does Uteplex work?
What is the generic name of Uteplex?
What drug class is Uteplex in?
What development phase is Uteplex in?
What does Uteplex target?
Related
- Drug class: All uridine triphosphate drugs
- Target: All drugs targeting P2Y purinoceptor 11, P2Y purinoceptor 4, P2Y purinoceptor 6
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing